Chemomab Therapeutics Announces Third Quarter 2024

2 days ago · Net Loss: Net loss was $3.5 million, or a net loss of approximately $0.01 per basic and diluted ordinary share for the third quarter of 2024, compared to $4.1 million, or a net loss …

CouponFollow Extension

$3
OFF

Chemomab Therapeutics Announces Third Quarter 2024

1 week from now

2 days ago · Net Loss: Net loss was $3.5 million, or a net loss of approximately $0.01 per basic and diluted ordinary share for the third quarter of 2024, compared to $4.1 million, or a net loss …

globenewswire.com

$10
OFF

Chemomab Therapeutics Announces Third Quarter 2024 Financial …

1 week from now

2 days ago · During the third quarter of 2024 Chemomab completed a private placement that resulted in gross proceeds to the company of approximately $10 million. Chemomab believes …

stocktitan.net

$17
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating

1 week from now

Spero reported a net loss of $17.1 million, or ($0.32) per share of common stock, basic and diluted, for the third quarter ended September 30, 2024, compared with a net loss of $3.2 …

nasdaq.com

$19
OFF

Chemomab Therapeutics Sees Cash Runway Through Beginning Of …

1 week from now

2 days ago · Cash and short-term bank deposits were $19.5 million as of September 30, 2024, as compared to $12.8 million as of June 30, 2024 and $19.9 million as of December 31, 2023. …

businessinsider.com

$17
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating

1 week from now

1 day ago · Third quarter 2024 Financial Results . Spero reported a net loss of $17.1 million, or ($0.32) per share of common stock, basic and diluted, for the third quarter ended September …

biospace.com

$2
OFF

Chemomab Therapeutics Announces Third Quarter 2024 …

1 week from now

2 days ago · Research and Development (R&D) Expenses: R&D expenses were $2.8 million for the third quarter of 2024, compared to $3.4 million for the third quarter of 2023. The decrease …

chemomab.com

$2417304
OFF

The Healthcare Foundation Of NJ Announces $2,417,304 In Third …

1 week from now

Sep 18, 2024 · The Healthcare Foundation of NJ (HFNJ) is pleased to announce that it has awarded $2,417,304 to eighteen nonprofit organizations in its third quarterly grant cycle of …

hfnj.org

FAQs about Chemomab Therapeutics Announces Third Quarter 2024 Coupon?

Will chemomab be able to fund its operations in 2026?

Chemomab believes its existing liquidity resources as of September 30, 2024, will enable the company to fund its operations through the beginning of 2026. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. ...

How much money did chemomab make in 2024?

Cash and short-term bank deposits were $19.5 million as of September 30, 2024, as compared to $12.8 million as of June 30, 2024 and $19.9 million as of December 31, 2023. During the third quarter of 2024 Chemomab completed a private placement that resulted in gross proceeds to the company of approximately $10 million. ...

How do I contact chemomab after a press release is issued?

Investors who would like to discuss the financial results or business update after the press release has been issued are invited to contact the company at [email protected]. Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. ...

Who is chemomab Therapeutics?

Chemomab Therapeutics is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions that involve inflammation and fibrosis and have high unmet need. Fibrosis-related diseases are a significant unmet need that dramatically affect patients' health and quality of life. ...

When will chemomab's CM-101 PSC Phase 2 Spring trial results be presented?

On October 15, 2024, Chemomab announced that on November 18, 2024, PSC expert Dr. Christopher Bowlus will be presenting a late-breaking oral presentation discussing the CM-101 PSC Phase 2 SPRING trial results at the AASLD The Liver Meeting ® 2024. ...

What happened to chemomab?

On July 30, 2024, Chemomab announced the closing of a private placement that resulted in gross proceeds of approximately $10 million to the company. Existing investors such as OrbiMed and new investors including HBM Partners and Sphera Biotech Master Fund participated in the financing. ...